TY - JOUR
T1 - Ultrasound Molecular Imaging
T2 - Principles and Applications in Cardiovascular Medicine
AU - Brown, Eran
AU - Lindner, Jonathan R.
N1 - Funding Information:
Conflict of Interest Eran Brown grants from American Heart Association (Grant: 18PRE33960532). Jonathan R. Lindner reports grants from GE Lifesciences.
Funding Information:
Funding Information Mr. Brown is supported by grant 18PRE33960532 from the American Heart Association; Dr. Lindner is supported by grants R01-HL078610, R01-HL120046, and P51-OD011092 from the National Institutes of Health (NIH).
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Purpose of Review: Non-invasive molecular imaging is currently used as a research technique to better understand disease pathophysiology. There are also many potential clinical applications where molecular imaging may provide unique information that allows either earlier or more definitive diagnosis, or can guide precision medicine-based decisions on therapy. Contrast-enhanced ultrasound (CEU) with targeted microbubble contrast agents is one such technique that has been developed that has the unique properties of providing rapid information and revealing information only on events that occur within the vascular space. Recent Findings: CEU molecular probes have been developed for a wide variety of disease states including atherosclerosis, vascular inflammation, thrombosis, tumor neovascularization, and ischemic injury. While the technique has not yet been adapted to clinical use, it has been used to reveal pathological processes, to identify new therapeutic targets, and to test the efficacy of novel treatments. Summary: This review will explore the physical basis for CEU molecular imaging, its strengths and limitations compared to other molecular imaging modalities, and the pre-clinical translational research experience.
AB - Purpose of Review: Non-invasive molecular imaging is currently used as a research technique to better understand disease pathophysiology. There are also many potential clinical applications where molecular imaging may provide unique information that allows either earlier or more definitive diagnosis, or can guide precision medicine-based decisions on therapy. Contrast-enhanced ultrasound (CEU) with targeted microbubble contrast agents is one such technique that has been developed that has the unique properties of providing rapid information and revealing information only on events that occur within the vascular space. Recent Findings: CEU molecular probes have been developed for a wide variety of disease states including atherosclerosis, vascular inflammation, thrombosis, tumor neovascularization, and ischemic injury. While the technique has not yet been adapted to clinical use, it has been used to reveal pathological processes, to identify new therapeutic targets, and to test the efficacy of novel treatments. Summary: This review will explore the physical basis for CEU molecular imaging, its strengths and limitations compared to other molecular imaging modalities, and the pre-clinical translational research experience.
KW - Contrast-enhanced ultrasound
KW - Microbubbles
KW - Molecular imaging
KW - Targeted ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85063157954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063157954&partnerID=8YFLogxK
U2 - 10.1007/s11886-019-1117-9
DO - 10.1007/s11886-019-1117-9
M3 - Review article
C2 - 30887129
AN - SCOPUS:85063157954
SN - 1523-3782
VL - 21
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 5
M1 - 30
ER -